Most respondents in the United States had been using cannabidiol (CBD) for a relatively short amount of time. Only 35 percent had used it for more than one year as of 2022.

The most commonly consumed dose of cannabidiol (CBD) among respondents in the United States in 2022 was between five and ten milligrams. Twenty-two percent of respondents either didn't know how much they consumed or did not check dosage.

Melatonin was the best selling ingredient in supplements for sleep in the United States in 2021. Sales of supplements including the ingredient reached over 14 million U.S. dollars in that year.

CBD product manufacturers are fresh from a whirlwind five-year stretch that's seen every primary market driver—input prices, consumer demand and regulation—rapidly evolve. Early pandemic anxiety and shifting wellness priorities sparked surging first-time use, feeding a wave of new manufacturers and fueling unprecedented growth. But as the market matured, rising input costs, abrupt regulatory changes and tightening retailer standards ushered in a tougher, more fragmented playbook. Gone are the days when novelty and mass SKU expansion alone could move the needle. Instead, we're seeing an industry marked by heightened operational discipline, defensive pivots into compliant topicals and ingestibles and a sharp shakeout of less resilient brands. Employment is now consolidated among larger, nimble producers with deep channel partnerships, efficient co-manufacturing relationships and the ability to readjust product mixes quickly. Revenue has been expanding at a CAGR of 8.0% over the past five years, bolstered mainly by early-period, double-digit growth. In 2025, revenue fell 2.5%, totalling $1.3 billion. Leading retailers have installed steep onboarding barriers, demanding bulletproof documentation, QA and supply-chain transparency. Many smaller and early-stage manufacturers—unable to invest in new requirements—are either losing placements or exiting altogether. This gating effect has accelerated the concentration of sales among the best-prepared producers, particularly those specializing in pharmacy- or beauty-channel SKUs. Meanwhile, input price volatility remains a thorn in the industry's side, repeatedly forcing producers to recalibrate pricing, delay launches and reduce promotional activity. These dynamics fuel competitive churn: top operators are scaling up with high-efficiency runs and broader channel access, while less adaptable brands face permanent contraction. The stage is set for a strategic transformation led by pharmaceutical-grade integration, AI-driven personalization and consolidation through 2030. Forward-thinking manufacturers will drive industry evolution by investing in clinical-grade manufacturing, robust data systems and flexible, personalized product lines. Market growth should be steadier, if less meteoric, as an expected set of regulatory reforms around over-the-counter access and supply-chain traceability further favor scalable, compliant leaders. The emergence of a handful of platform-scale producers—armed with the infrastructure to secure premium contracts, rapid manufacturing runs and national retail access—isn't just likely, it's fast becoming a prerequisite for industry dominance. Those able to blend pharmaceutical credibility, operational agility and regulatory foresight are expected to command the lion's share of revenue moving forward. Revenue is forecast to expand at a CAGR of 6.5% over the next five years, reaching $1.7 billion in 2030.

Tinctures were the top selling CBD product in the United States in 2021. Tinctures represented a market value of nearly *********** U.S. dollars in that year. The second most popular product category was topicals at a value of over *********** dollars.

Number of Businesses statistics on the CBD Product Manufacturing industry in the US

Comprehensive dataset containing 6 verified Cbd locations in Texas, United States with complete contact information, ratings, reviews, and location data.

This statistic depicts the dollar sales of cannabidiol products derived from marijuana in the United States from 2017 to 2022, broken down by product content. In 2018, high THC cannabidiol products generated about ** million dollars in sales.

Sales of CBD products have exploded in the United States in the last year. In 2019, sales in the multioutlet retail channel grew by nearly *** percent compared to the previous year.

LANDFIRE's (LF) 2022 Canopy Bulk Density (CBD) describes the mass of available canopy fuel per unit canopy volume that would burn in a crown fire. A spatially explicit map of CBD supplies information used in fire behavior models to determine the spread characteristics of active crown fires across the landscape. CBD for disturbed and non-disturbed areas is determined via a general linear model (GLM) relating Canopy Height (CH) and Canopy Cover (CC) to CBD (Reeves et al 2009). In LF 2022, fuel products are created with LF 2016 Remap vegetation in areas that were un-disturbed in the last ten years. To designate disturbed areas where CBD is modified, the aggregated Annual Disturbance products from 2013 to 2022 in the Fuel Disturbance (FDist) product are used. All existing disturbances between 2013-2022 are represented in the LF 2022 update, and the products are intended to be used in 2023 (the year of release). The “capable” year terminology used in LF 2020 and LF 2016 Remap is no longer specified, due to reduction in latency from when a disturbance occurs to the release date of fuel products accounting for that disturbance. However, users should still consider adjusting fuel layers for disturbances that occurred after the end of the 2022 fiscal year (after October 1st, 2022) when using the LF 2022 fuel products. Because those changes would not be accounted for. Learn more about LF 2022 at https://landfire.gov/lf_230.php .

This statistic depicts the dollar sales of hemp-based cannabidiol products for pets and humans in the United States in 2017, with projected figures for 2022. In 2017, CBD products meant for human consumption generated about *** million U.S. dollars.

This statistic depicts the share of sales of cannabidiol products in the natural and specialty channel in the United States in 2017, with projected figures for 2022, broken down by product type. In 2017, CBD supplements accounted for ** percent of total sales. This share is expected to decrease to ** percent by 2022.

CBD infused bottled water was the top selling CBD (cannabidiol) beverage in the United States in 2019. Sales of the beverage reached over *** million U.S. dollars in that year.

California had the most cultivation licenses of any state in the United States in 2022, by far. That year, there were 6,881 such licenses in the state compared with 1,406 in Oregon. Recreational marijuana in the United States Starting with Colorado and Washington in 2012, the legalization of recreational marijuana has since then expanded across many other federal states in the United States including Arizona, California, New York, Michigan and the District of Columbia amongst others. As of January 2023, 21 states have legalized the recreational use of marijuana in the United States. With further legalization expected across the country, sales of recreational cannabis are expected to reach nearly 42 billion U.S. dollars by 2026. As the largest cannabis market in the U.S., California’s recreational marijuana sales are expected to exceed 7 billion U.S. dollars by 2024. CBD market in the United States Moving in tandem with the growing recreational marijuana market is the CBD (Cannabidiol) market in the United States. Similarly expected to experience expansive growth in the next few years, CBD dollar sales are forecast to reach 16 billion U.S. dollars by 2026. Amongst the best-selling CBD products in U.S. convenience stores in 2020 were cannabidiol supplements, sleeping remedies and external analgesic rubs.